RNTX
Rein Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$21K
5Y Perf.-47.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RNTX vs PULM
Revenue, margins, valuation, and 5-year total return — side by side.
PULM
Pulmatrix, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-81.4%
RNTX vs PULM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNTX | PULM |
|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology |
| Market Cap | $21K | $5M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-59M | $-5M |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $13M | $4M |
RNTX vs PULM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNTX
PULM
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Rein Therapeutics I… (RNTX) | 100 | 53.0 | -47.0% |
| Pulmatrix, Inc. (PULM) | 100 | 18.6 | -81.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNTX vs PULM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNTX leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Pulmatrix, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
RNTX
Rein Therapeutics Inc.
The Long-Run Compounder
RNTX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -44.8% 10Y total return vs PULM's -99.7%
- 16.7% revenue growth vs PULM's -100.0%
- -28.2% vs PULM's -79.3%
Best for: long-term compounding
PULM
Pulmatrix, Inc.
The Income Pick
PULM is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.68
- Rev growth -100.0%, EPS growth 46.2%
- Lower volatility, beta 0.68, current ratio 12.55x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNTX | 16.7% revenue growth vs PULM's -100.0% |
| Stability / Safety | PULM | Beta 0.68 vs RNTX's 1.36 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RNTX | -28.2% vs PULM's -79.3% |
| Efficiency (ROA) | RNTX | -109.6% ROA vs PULM's -124.7% |
RNTX vs PULM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2020
RNTX vs PULM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNTXLAGGINGPULM
PULMPulmatrix, Inc.
1leads
RNTXRein Therapeutics Inc.
2leads
6 Total Categories
CATEGORYLEADERvs PULMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PULM1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNTX4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
RNTX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PULM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RNTX and PULM operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$61M | -$5M |
| Net IncomeAfter-tax profit | -$59M | -$5M |
| Free Cash FlowCash after capex | -$21M | -$5M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +53.7% |
PULM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RNTX and PULM each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| Market CapShares × price | $20,987 | $5M |
| Enterprise ValueMkt cap + debt − cash | -$13M | $659,971 |
| Trailing P/EPrice ÷ TTM EPS | -0.33x | -0.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.25x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RNTX and PULM each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
RNTX leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
RNTX delivers a -127.5% return on equity — every $100 of shareholder capital generates $-127 in annual profit, vs $-135 for PULM. On the Piotroski fundamental quality scale (0–9), PULM scores 2/9 vs RNTX's 1/9, reflecting mixed financial health.
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -127.5% | -135.5% |
| ROA (TTM)Return on assets | -109.6% | -124.7% |
| ROICReturn on invested capital | -3.1% | — |
| ROCEReturn on capital employed | -78.9% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$13M | -$4M |
| Cash & Equiv.Liquid assets | $13M | $4M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
RNTX leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
RNTX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNTX five years ago would be worth $5,519 today (with dividends reinvested), compared to $727 for PULM. Over the past 12 months, RNTX leads with a -28.2% total return vs PULM's -79.3%. The 3-year compound annual growth rate (CAGR) favors RNTX at -18.0% vs PULM's -24.3% — a key indicator of consistent wealth creation.
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -6.4% | -42.5% |
| 1-Year ReturnPast 12 months | -28.2% | -79.3% |
| 3-Year ReturnCumulative with dividends | -44.8% | -56.7% |
| 5-Year ReturnCumulative with dividends | -44.8% | -92.7% |
| 10-Year ReturnCumulative with dividends | -44.8% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -18.0% | -24.3% |
RNTX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RNTX and PULM each lead in 1 of 2 comparable metrics.
Risk & Volatility
PULM is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than RNTX's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNTX currently trades 48.8% from its 52-week high vs PULM's 13.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 0.72x |
| 52-Week HighHighest price in past year | $2.40 | $9.37 |
| 52-Week LowLowest price in past year | $1.00 | $1.16 |
| % of 52W HighCurrent price vs 52-week peak | +48.8% | +13.9% |
| RSI (14)Momentum oscillator 0–100 | 40.0 | 44.8 |
| Avg Volume (50D)Average daily shares traded | 541K | 59K |
Evenly matched — RNTX and PULM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RNTXRein Therapeutics… | PULMPulmatrix, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RNTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). PULM leads in 1 (Income & Cash Flow). 2 tied.
Best OverallRein Therapeutics Inc. (RNTX)Leads 2 of 6 categories
Loading custom metrics...
RNTX vs PULM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — RNTX or PULM?
Over the past 5 years, Rein Therapeutics Inc.
(RNTX) delivered a total return of -44. 8%, compared to -92. 7% for Pulmatrix, Inc. (PULM). Over 10 years, the gap is even starker: RNTX returned -42. 5% versus PULM's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — RNTX or PULM?
By beta (market sensitivity over 5 years), Pulmatrix, Inc.
(PULM) is the lower-risk stock at 0. 72β versus Rein Therapeutics Inc. 's 1. 37β — meaning RNTX is approximately 90% more volatile than PULM relative to the S&P 500.
03Which is growing faster — RNTX or PULM?
On earnings-per-share growth, the picture is similar: Pulmatrix, Inc.
grew EPS 46. 2% year-over-year, compared to -2. 6% for Rein Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — RNTX or PULM?
Rein Therapeutics Inc.
(RNTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Pulmatrix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNTX leads at 0. 0% versus 0. 0% for PULM. At the gross margin level — before operating expenses — RNTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RNTX or PULM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RNTX or PULM better for a retirement portfolio?
For long-horizon retirement investors, Pulmatrix, Inc.
(PULM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Both have compounded well over 10 years (PULM: -99. 7%, RNTX: -42. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RNTX and PULM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.